top of page
MedMira receives Health Canada approval for its Reveal® G4 Rapid HIV-1/2 Test for Point-of-Care use
Halifax, Nova Scotia – January 14, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today the approval from...
MedMira
Jan 143 min read
MedMira receives investigational testing authorization for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Halifax, Nova Scotia,  9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing...
MedMira
Jan 94 min read
MedMira receives Health Canada approval for its Multiplo® Rapid (TP/HIV) Test for Syphilis and HIV
Halifax, Nova Scotia - December 24, 2024 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24,...
MedMira
Dec 24, 20245 min read
MedMira Announces the appointment of Vice President of Commercial Operations
Halifax, Nova Scotia, October 3, 2024  – Today, MedMira Inc. (MedMira) (TSXV: MIR) today announced the appointment of Nicole Crenshaw as...
MedMira
Oct 3, 20243 min read
Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its...
MedMira
Aug 13, 20245 min read
Miriad MultiLinx - One Test, More Answers
Introducing MedMira's latest product now available anywhere for Tissue and Eye Banks: Miriad MultiLinx: One Test, More Answers. The...
MedMira
Jun 12, 20241 min read
bottom of page